CALIFORNIA NANOTECHNOLOGIES (CNO.CA) Stock Fundamental Analysis

Canada - TSX Venture Exchange - TSX-V:CNO - CA1304921010 - Common Stock

0.385 CAD

+0.02 (+4.05%)

Last: 1/23/2026, 7:00:00 PM

Fundamental Rating

CNO gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 22 industry peers in the Machinery industry. While CNO seems to be doing ok healthwise, there are quite some concerns on its profitability. CNO is valued correctly, but it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year CNO has reported negative net income.
CNO had a positive operating cash flow in the past year.
In multiple years CNO reported negative net income over the last 5 years.
CNO had a positive operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of CNO (-21.51%) is worse than 68.18% of its industry peers.
Looking at the Return On Equity, with a value of -39.65%, CNO is in line with its industry, outperforming 40.91% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-21.51%
ROE	-39.65%
ROIC	N/A

ROA(3y)7%

ROA(5y)3.17%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

In the last couple of years the Operating Margin of CNO has grown nicely.
CNO has a Gross Margin of 69.19%. This is amongst the best in the industry. CNO outperforms 95.45% of its industry peers.
CNO's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for CNO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	69.19%

OM growth 3Y4.57%

OM growth 5Y69.99%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y1.75%

GM growth 5Y3.23%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CNO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CNO has been increased compared to 1 year ago.
The number of shares outstanding for CNO has been increased compared to 5 years ago.
The debt/assets ratio for CNO is higher compared to a year ago.

2.2 Solvency

An Altman-Z score of 3.13 indicates that CNO is not in any danger for bankruptcy at the moment.
CNO has a Altman-Z score of 3.13. This is in the better half of the industry: CNO outperforms 77.27% of its industry peers.
The Debt to FCF ratio of CNO is 4.46, which is a neutral value as it means it would take CNO, 4.46 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 4.46, CNO belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
CNO has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.49, CNO is in line with its industry, outperforming 54.55% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.49
Debt/FCF	4.46
Altman-Z	3.13

ROIC/WACCN/A

WACC9.67%

2.3 Liquidity

A Current Ratio of 1.19 indicates that CNO should not have too much problems paying its short term obligations.
CNO's Current ratio of 1.19 is on the low side compared to the rest of the industry. CNO is outperformed by 72.73% of its industry peers.
CNO has a Quick Ratio of 1.19. This is a normal value and indicates that CNO is financially healthy and should not expect problems in meeting its short term obligations.
CNO has a Quick ratio of 1.19. This is in the better half of the industry: CNO outperforms 72.73% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.19
Quick Ratio	1.19

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for CNO have decreased strongly by -477.78% in the last year.
Looking at the last year, CNO shows a very negative growth in Revenue. The Revenue has decreased by -17.79% in the last year.
CNO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 49.59% yearly.

EPS 1Y (TTM)-477.78%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%57.82%

Revenue 1Y (TTM)-17.79%

Revenue growth 3Y79.21%

Revenue growth 5Y49.59%

Sales Q2Q%-48.76%

3.2 Future

Based on estimates for the next years, CNO will show a very strong growth in Earnings Per Share. The EPS will grow by 103.23% on average per year.
The Revenue is expected to decrease by -10.42% on average over the next years. This is quite bad

EPS Next Y100%

EPS Next 2Y103.23%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year-41.31%

Revenue Next 2Y-10.42%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

CNO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 27.06, CNO can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, CNO is valued a bit cheaper than the industry average as 72.73% of the companies are valued more expensively.
CNO is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 24.26, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	27.06

4.2 Price Multiples

The rest of the industry has a similar Enterprise Value to EBITDA ratio as CNO.
CNO's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. CNO is cheaper than 68.18% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	42.45
EV/EBITDA	120.07

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CNO's earnings are expected to grow with 103.23% in the coming years.